Changing dopamine agonist treatment in Parkinson's disease: Experiences with switching to pramipexole

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 17-25

  Reichmann, H ^a   Odin, P ^b   Brecht, H M ^c   Koster J ^c   Kraus, P H ^d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Central Hospital Bremerhaven   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; BENZOTHIAZOLE DERIVATIVE; PRAMIPEXOL; UNCLASSIFIED DRUG;

AGED; ANHEDONIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NAUSEA; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG POTENTIATION; EVALUATION; HOSPITALIZATION; MOTOR ACTIVITY; PARKINSONISM; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; PSYCHOMOTOR PERFORMANCE; RETROSPECTIVE STUDY;

AGED; BENZOTHIAZOLES; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PSYCHOMOTOR PERFORMANCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREMOR;

EID: 34248580958     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-33328-0_2     Document Type: Article

References (33)

1. American Academy of Neurology, Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: Initiation of treatment for Parkinson's disease: An evidence based review. Neurology 58: 11-17
2. Agency for Healthcare Research and Quality (2003) Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature. Summary, Evidence Report/Technology Assessment: Number 57. AHRQ Publication Number 03-E039. Rockville, MD
3. Bain P (1993) A combined clinical and neurophysiological approach to the study of patients with tremor. J Neurol Neurosurg Psychiatry 56: 839-844
4. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey Jr RB (2004) Pergolide use in Parkinson's disease is associated with cardiac valve regurgitation. Neurology 63: 301-304
5. Brecht HM (2001) Dopaminagonisten im Vergleich. In: Riederer P, Laux G, Pöldinger W (eds) Neuro-Psychopharmaka 5: 226-237
6. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, van Zandijcke M, de Sutter J, Santens P, Decoodt P, Moerman Ch Schoors D (2004) Treatment of Parkinson's disease with pergolide and relation to restrictive valvular disease. The Lancet 363: 1179-1183
7. Canesi M, Antonini A, Mariani CB, Tesei S, Zecchinelli AL, Barichella M, Pezzoli G (1999) An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication. J Neural Transm 106: 925-929
8. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans D (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression Anxiety 11: 58-65
9. Etminan M, Sudeep G, Samii A (2003) Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease. A Meta-Analysis. Drug Safety 26: 439-444
10. Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78: 730-731
11. German Society of Neurology (2003) Leitlinien für Diagnostik und Therapie in der Neurologie; 2. revised and enlarged edition, Thieme, Stuttgart, New York
12. Gimenez-Roldan S, Esteban EM, Mateo D (2001) Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 24: 346-351
13. Goetz CG, Blasucci L, Stebbins GT (1999) Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 52: 1227-1229
14. Grosset K, Needleman F, Macphee G, Grosset D (2004) Switching from ergot to nonergot dopamine agonists in Parkinson's disease: A clinical series and five-drug dose conversion table. Mov Disord 19: 1370-1374
15. Hanna PA, Ratkos L, Ondo WG, Jankovic J (2001) Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm 108: 63-70
16. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19: 656-662
17. Kraus P, Hoffmann A (2006) (in preparation) Spiralometry: A new technique for a computer based evaluation of paper-pencil spirals
18. Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H (2005) Anhedonia, Depression and Motor Functioning in Parkinson's Disease during treatment with Pramipexole. J Neuropsychiatry Clin Neurosci 17: 214-220
19. Linazasoro G (2004) Spanish Dopamine Agonists Study Group: conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 251: 335-339
20. Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martinez-Martin P, Bonuccelli U, Kraus PH, van Hilten JJ (2004) A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 75: 388-395
21. 4 receptors. Eur J Pharmacol 290: 29-36
22. Müller Th, Fritze J (2003) Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clinical Neuropharmacol 26: 109-111
23. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 56 [Suppl 5]: S1-S88
24. Pogarell O, Gasser T, Van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH (2002) Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72: 713-720
25. Rabey JM, Bass H, Bonucelli U, Brooks D, Klotz P, Korczyn AD, Kraus P, Martinez-Martin P, Morrish P, van Sauten W, van Hilten B (1997) Evaluation of the short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 20: 322-337
26. Rascol O, Pathak A, Bagheri H, Montastruc JL (2004) New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 19: 611-613
27. Reichmann H, Brecht HM, Köster J, Kraus PH (2003) Pramipexole in routine clinical practice. CNS Drugs 17: 965-973
28. Reichmann H, Herting B, Miller A, Sommer U (2003) Switching and combining dopamine agonists. J Neural Transm 110: 1393-1400
29. Reichmann H, Sommer U, Fuchs G, Hefter H, Mark G, Muller T, Thumler R, Ulm G, Vieregge P (2000) Workshop IV: drug treatment guidelines for the long-term management of parkinson's disease. J Neurol 247 [Suppl 4]: 40-41
30. Rektorova I, Rektor I, Bares M, Dostál V, Ehler E, Fanfrdiovà Z, Fiedler J, Klaiblova H, Kulisták P, Ressner P, Svátová J, Urbánek K, Velísková J (2003) Depression in Parkinson's disease: an eight-month, randomised, open-label, national multi-centre comparative study of pramipexole and pergolide. Eur J Neurol 10: 399-406
31. Stewart D, Morgan E, Burn D, Grosset D, Chaudhuri KR, MacMahon D, Needleman F, Macphee G, Heywood P (2004) Dopamine agonist switching in Parkinson's disease. Hosp Med 65: 215-219
32. Tan EK, Ratnagopal P, Han SY, Wong MC (2003) Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study. Acta Neurol Scand 107: 202-206
33. Tetrud JW, Zhang J, Gomez-Mancilla B, Greenfield JC (2000) Abrupt conversion of Parkinson's disease patients to pramipexole from bromocriptine or pergolide: Safety, tolerance, and optimal conversion ratio. Neurology 54 [Suppl 3]: 279-280